Penserra Capital Management
ESPR icon

Penserra Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Penserra Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-645
Closed -$7K – 1421
2021
Q3 		$7K Buy
645
+5
+0.8% +$73 ﹤0.01% 1391
2021
Q2 		$13K Buy
640
+5
+0.8% +$120 ﹤0.01% 1251
2021
Q1 		$17K Sell
635
-5
-0.8% -$148 ﹤0.01% 986
2020
Q4 		$16K Buy
640
+404
+171% +$12.1K ﹤0.01% 874
2020
Q3 		$8K Buy
+236
New +$9.35K ﹤0.01% 834

Other funds holding ESPR

Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Deerfield Management
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Bellevue Group
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Penserra Capital Management's ESPR Position: Q4 2021 in Review

Penserra Capital Management sold out of Esperion Therapeutics (ESPR) in Q4 2021, closing a stake of 645 shares — an estimated $7K sold.

Penserra Capital Management first reported a position in ESPR in Q3 2020 and held it in 5 quarters. The position peaked at $17K in Q1 2021. 133 funds tracked by Wall St. Rank hold ESPR as of Q4 2021.

  • Penserra Capital Management reported no remaining Esperion Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 645 Esperion Therapeutics shares in Q4 2021, an estimated $7K.
  • Penserra Capital Management first reported a position in Esperion Therapeutics in Q3 2020 and held it in 5 quarters.
  • Penserra Capital Management's Esperion Therapeutics position peaked at $17K in Q1 2021.
  • 133 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.